We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-17.92%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$999M
AUM Growth
-$111M
Cap. Flow
+$163M
Cap. Flow %
16.29%
Top 10 Hldgs %
53.54%
Holding
68
New
18
Increased
13
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$73.3M
2
XNCR icon
Xencor
XNCR
+$36.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$33.3M
4
SLDB icon
Solid Biosciences
SLDB
+$27.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$25.8M

Top Sells

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$31.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.6M
3
KYNB
Kyntra Bio
KYNB
+$22.2M
4
SRRK icon
Scholar Rock
SRRK
+$20.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 77.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFMD
51
DELISTED
Affimed
AFMD
$492K 0.05%
+15,822
New +$588K
CNST
52
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$318K 0.03%
79,194
-200,806
-72% -$1.21M
PRQR icon
53
ProQR Therapeutics
PRQR
$240M
$174K 0.02%
+11,022
New +$202K
ASMB icon
54
CALL
Assembly Biosciences
ASMB
$531M
– –
-12,342
Closed -$5.5M
ELAN icon
55
Elanco Animal Health
ELAN
$12.9B
– –
-190,000
Closed -$6.63M
MGNX icon
56
MacroGenics
MGNX
$285M
– –
-1,481,086
Closed -$31.8M
MRSN
57
DELISTED
Mersana Therapeutics
MRSN
– –
-19,825
Closed -$4.96M
RARE icon
58
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-325,000
Closed -$24.8M
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-254,000
Closed -$19.4M
SPRO icon
60
Spero Therapeutics
SPRO
$91.5M
– –
-892,741
Closed -$9.38M
TECX
61
Tectonic Therapeutic
TECX
$615M
– –
-5,721
Closed -$3.56M
PHXM
62
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
– –
-6,957
Closed -$590K
INFI
63
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-462,068
Closed -$1.25M
APTX
64
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-41,037
Closed -$1.19M
JNCE
65
CALL
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-497,400
Closed -$3.23M
KDMN
66
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-1,480,870
Closed -$4.95M
FTSV
67
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-99,000
Closed -$1.48M
ACHN
68
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,564,080
Closed -$5.76M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q4 2018 Portfolio in Review

As of Q4 2018, EcoR1 Capital held 68 positions worth $999M, down 10% from $1.11B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

EcoR1 Capital deployed $163M of net new capital in Q4 2018, opening 18 new positions and adding to 13 existing holdings. Its largest new stake was argenx: 825,087 shares worth $79.3M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.6M trimmed.

  • EcoR1 Capital's largest Q4 2018 buy was argenx: 825,087 shares worth $79.3M.
  • EcoR1 Capital added most to Ionis Pharmaceuticals in Q4 2018, an estimated $33.3M increase.
  • EcoR1 Capital's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.6M.
  • EcoR1 Capital fully exited MacroGenics in Q4 2018, selling an estimated $31.8M.
  • EcoR1 Capital's ten largest holdings make up 54% of its $999M portfolio in Q4 2018.
  • EcoR1 Capital opened 18 new positions and closed 15 in Q4 2018.
  • EcoR1 Capital's portfolio value fell 10% quarter-over-quarter to $999M.

Based on EcoR1 Capital's 13F filing for Q4 2018, filed 14 Feb 2019.